IRF5-TNPO3 locus: Inclusion of TNPO3 as a unique regulator of IRF5 expression an
IRF5-TNPO3 基因座:将 TNPO3 作为 IRF5 表达的独特调节因子纳入其中
基本信息
- 批准号:8664081
- 负责人:
- 金额:$ 20.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAlternative SplicingAmericanArginineAutoantibodiesAutoimmune DiseasesB-LymphocytesBlood CellsCell NucleusCellsChromosomes, Human, Pair 7ClinicalComplexDataDiabetes MellitusDiseaseFaceFamilyFlow CytometryGene ExpressionGenesGeneticGenetic PolymorphismGenetic RiskGenetic VariationGenotypeGoalsHaplotypesHealthHeart DiseasesHeterogeneityHuman GeneticsIL6 geneImageImmuneImmune responseImmunityImmunoblot AnalysisImmunologicsImmunoprecipitationImportinsInterferonsInterleukin-10Interleukin-12JointsKaryopherinsKnowledgeLupusMalignant NeoplasmsMediatingNuclearNuclear AntigensNuclear ImportNuclear Localization SignalNuclear Pore Complex ProteinsPathogenesisPathologyPathway interactionsPatientsPeripheral Blood Mononuclear CellPlayPopulationPredispositionPrevalenceProcessProductionProtein ImportProteinsPublishingRNA SplicingRegulationResearch ProposalsReverse Transcriptase Polymerase Chain ReactionRheumatoid ArthritisRiskRoleSamplingSelf ToleranceSerineSerumSingle Nucleotide PolymorphismSystemic Lupus ErythematosusTechnologyTestingTranscriptTumor Necrosis Factor-alphaUnited States National Institutes of HealthValidationWorkbasechemokinechemokine receptorcohortcytokinedesigndisease phenotypedisorder riskdrug discoveryfluorescence imaginggenetic variantgenome wide association studyhuman ARMET proteininsightlymphoblastoid cell linemembernext generation sequencingnoveloverexpressionprotein expressionprotein functionprototypereceptorreceptor expressionstatisticstranscription factortranscriptome sequencing
项目摘要
DESCRIPTION (provided by applicant):
Project Summary The NIH estimates up to 23.5 million Americans suffer from autoimmune diseases and that the prevalence is rising; this statistic is higher than the number of Americans having cancer (9 million) or heart disease (22 million). Systemic lupus erythematosus (SLE) is the third most frequent autoimmune disease affecting approximately 1 in 2000 people. It is the prototype of complex autoimmune diseases and is characterized by extreme breakdown of self-tolerance resulting in multiple immunologic abnormalities. Cures are not yet available for SLE and patients face a lifetime of illness and treatment. Given the clinical heterogeneity of this disease, combined with limited knowledge of pathogenesis, designing new treatment options has been difficult. Recent findings from joint linkage and genome-wide association studies (GWAS) have provided significant insight into the genes and pathways contributing to disease pathogenesis. SLE is highly heritable with a strong genetic component that includes the interferon regulatory factor 5 (IRF5)-transportin 3 (TNPO3) region. Genetic variants in the IRF5-TNPO3 locus have been associated with SLE risk in every published study testing this region and in every ethnic population. Although some effort has recently gone into studying the functional consequence of genetic variants in IRF5, few studies have included an analysis of TNPO3 expression and function in SLE. The primary goal of this research proposal is to determine how the IRF5-TNPO3 locus alters SLE disease risk by experimentally bridging the gap(s) in knowledge between identification of this causal locus and its actual functional influence on SLE risk. IRF5 encodes a transcription factor central to the innate and adaptive immune response through its regulation of key processes including cytokine production, chemokine and chemokine receptor expression, and autoantibody production. TNPO3 is a member of the importin family and encodes a nuclear import receptor that mediates nuclear entry of serine/arginine (SR)-rich proteins such as splicing factors SFRS1 and SFRS2. Based on recent experimental findings from our lab, we hypothesize that the genetic risk coming from the IRF5-TNPO3 locus is not solely from IRF5 and directly involves TNPO3 function via its ability to regulate novel mechanisms controlling IRF5 alternative splicing and nuclear localization. This hypothesis will be tested in the following Specific Aims: 1) Determine the level of IRF5 and TNPO3 transcript and protein expression in immune cells from healthy donors and SLE patients carrying the risk and non-risk haplotypes at IRF5-TNPO3 SNPs, 2) Determine whether TNPO3 controls IRF5 transcript expression through its ability to regulate the import of SR proteins to the nucleus, and 3) Determine whether IRF5, TNPO3 and NUP62 differentially interact in genotyped healthy donor and SLE immune cells resulting in altered IRF5 nuclear localization. Results from this study will bridge the gap between disease- associated genetic variation, gene expression, protein function, and disease phenotype, and identify novel mechanisms that can be therapeutically targeted to regulate IRF5 expression and activation in SLE.
描述(由申请人提供):
美国国立卫生研究院估计,多达2350万美国人患有自身免疫性疾病,患病率正在上升;这一统计数据高于美国癌症(900万)或心脏病(2200万)的人数。系统性红斑狼疮(SLE)是第三常见的自身免疫性疾病,约2000人中有1人患病。它是复杂自身免疫性疾病的原型,其特征是自身耐受性的极端破坏,导致多种免疫异常。SLE的治愈方法还没有,患者面临终身的疾病和治疗。鉴于这种疾病的临床异质性,加上对发病机制的认识有限,设计新的治疗方案一直很困难。联合连锁和全基因组关联研究(GWAS)的最新发现为疾病发病机制的基因和途径提供了重要的见解。SLE具有高度遗传性,具有很强的遗传成分,包括干扰素调节因子5(IRF 5)-转运蛋白3(TNPO 3)区域。IRF 5-TNPO 3基因座的遗传变异与SLE风险相关,在每一个已发表的研究测试该地区和每个种族人群。虽然最近已经有一些努力研究IRF 5遗传变异的功能后果,但很少有研究包括分析TNPO 3在SLE中的表达和功能。本研究的主要目标是通过实验弥合IRF 5-TNPO 3基因座的识别与其对SLE风险的实际功能影响之间的知识差距,确定IRF 5-TNPO 3基因座如何改变SLE疾病风险。IRF 5编码一种转录因子,该转录因子通过其调节关键过程(包括细胞因子产生、趋化因子和趋化因子受体表达以及自身抗体产生)对先天性和适应性免疫应答起中心作用。TNPO 3是输入蛋白家族的成员,编码一种核输入受体,介导富含丝氨酸/精氨酸(SR)的蛋白质(如剪接因子SFRS 1和SFRS 2)进入核。基于我们实验室最近的实验结果,我们假设来自IRF 5-TNPO 3基因座的遗传风险不仅仅来自IRF 5,而是通过其调节控制IRF 5选择性剪接和核定位的新机制的能力直接涉及TNPO 3功能。将在以下具体目标中检验这一假设:1)确定来自健康供体和SLE患者的免疫细胞中IRF 5和TNPO 3转录物和蛋白质表达的水平,所述健康供体和SLE患者在IRF 5-TNPO 3 SNP处携带风险和非风险单倍型,2)确定TNPO 3是否通过其调节SR蛋白质向细胞核的输入的能力来控制IRF 5转录物表达,和3)确定IRF 5,TNPO 3和NUP 62在基因型健康供体和SLE免疫细胞中差异性相互作用,导致IRF 5核定位改变。本研究的结果将弥合疾病相关遗传变异、基因表达、蛋白质功能和疾病表型之间的差距,并确定可以在治疗上靶向调节SLE中IRF 5表达和激活的新机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Betsy J Barnes其他文献
Betsy J Barnes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Betsy J Barnes', 18)}}的其他基金
Implications for Speckled proteins 110 and 140 in adaptive immunity
斑点蛋白 110 和 140 对适应性免疫的影响
- 批准号:
10726020 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
New role(s) for IRF5 as a regulator of tau accumulation in Alzheimer’s disease
IRF5 在阿尔茨海默病中调节 tau 蛋白积累的新作用
- 批准号:
10302599 - 财政年份:2021
- 资助金额:
$ 20.99万 - 项目类别:
IRF5 and Macrophage Activation Syndrome in systemic Juvenile Idiopathic Arthritis
系统性幼年特发性关节炎中的 IRF5 和巨噬细胞激活综合征
- 批准号:
10199939 - 财政年份:2019
- 资助金额:
$ 20.99万 - 项目类别:
Investigating monocyte dysfunction in Down Syndrome
研究唐氏综合症的单核细胞功能障碍
- 批准号:
10854106 - 财政年份:2019
- 资助金额:
$ 20.99万 - 项目类别:
IRF5 and Macrophage Activation Syndrome in systemic Juvenile Idiopathic Arthritis
系统性幼年特发性关节炎中的 IRF5 和巨噬细胞激活综合征
- 批准号:
10454915 - 财政年份:2019
- 资助金额:
$ 20.99万 - 项目类别:
IRF5 and Macrophage Activation Syndrome in systemic Juvenile Idiopathic Arthritis
系统性幼年特发性关节炎中的 IRF5 和巨噬细胞激活综合征
- 批准号:
9982787 - 财政年份:2019
- 资助金额:
$ 20.99万 - 项目类别:
IRF5 and Macrophage Activation Syndrome in systemic Juvenile Idiopathic Arthritis
系统性幼年特发性关节炎中的 IRF5 和巨噬细胞激活综合征
- 批准号:
10663266 - 财政年份:2019
- 资助金额:
$ 20.99万 - 项目类别:
Determining the function of IRF5 tumor suppressor in HCV pathogenesis
确定 IRF5 抑癌基因在 HCV 发病机制中的功能
- 批准号:
9108325 - 财政年份:2015
- 资助金额:
$ 20.99万 - 项目类别:
Determining the function of IRF5 tumor suppressor in HCV pathogenesis
确定 IRF5 抑癌基因在 HCV 发病机制中的功能
- 批准号:
9147052 - 财政年份:2015
- 资助金额:
$ 20.99万 - 项目类别:
IRF5-TNPO3 locus: Inclusion of TNPO3 as a unique regulator of IRF5 expression an
IRF5-TNPO3 基因座:将 TNPO3 作为 IRF5 表达的独特调节因子纳入其中
- 批准号:
9220283 - 财政年份:2014
- 资助金额:
$ 20.99万 - 项目类别:
相似海外基金
Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
- 批准号:
488788 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Operating Grants
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
- 批准号:
10638347 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
- 批准号:
10717440 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
- 批准号:
10577186 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
- 批准号:
10749474 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
- 批准号:
10673458 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
- 批准号:
2884151 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
- 批准号:
10660668 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
- 批准号:
2239056 - 财政年份:2023
- 资助金额:
$ 20.99万 - 项目类别:
Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
- 批准号:
468851650 - 财政年份:2022
- 资助金额:
$ 20.99万 - 项目类别:
Research Grants